Criteria and prediction models for mismatch repair gene mutations: a review
Aung Ko Win,1 Robert J MacInnis,1,2 James G Dowty,1 Mark A Jenkins1

ABSTRACT
One of the strongest predictors of colorectal cancer risk is carrying a germline mutation in a DNA mismatch repair (MMR) gene. Once identified, mutation carriers can be recommended for intensive screening that will substantially reduce their high colorectal cancer risk. Conversely, the relatives of carriers identified as noncarriers can be relieved of the burden of intensive screening. Criteria and prediction models that identify likely mutation carriers are needed for cost-effective, targeted, germline testing for MMR gene mutation. We reviewed 12 criteria/guidelines and 8 prediction models (Leiden, Amsterdam-plus, Amsterdam-alternative, MMRpro, PREMM,1,2,6, MMRpredict, Associazione Italiana per lo studio della Familiarità ed Ereditarietà dei tumori Gastrotestinali (AIFEG) and the Myriad Genetics Prevalence table) for identifying mutation carriers. While criteria are only used to identify individuals with colorectal cancer (yes/no for screening followed by germline testing), all prediction models except MMRpredict and Myriad tables can predict the probability of carrying mutations for individuals with or without colorectal cancer. We conducted a meta-analysis of the discrimination performance of 17 studies that validated the prediction models. The pooled estimate for the area under curve was 0.80 (95% CI 0.72 to 0.88) for MMRpro, 0.81 (95% CI 0.73 to 0.88) for MMRpredict, 0.84 (95% CI 0.81 to 0.88) for PREMM, and 0.85 (95% CI 0.78 to 0.91) for Leiden model. Given the high degree of overlap in the CIs, we cannot state that one model has a higher discrimination than any of the others. Overall, the existing statistical models have been shown to be sensitive and specific (at a 5% cut-off) in predicting MMR gene mutation carriers. Future models may need to: provide prediction of PMS2 mutations, take into account a wider range of Lynch syndrome-associated cancers when assessing family history, and be applicable to all people irrespective of any cancer diagnosis.

INTRODUCTION
Lynch syndrome (OMIM 120435), previously termed Hereditary Non-Polyposis Colorectal Cancer (HNPPC),1 is an autosomal dominantly inherited disorder of cancer susceptibility caused by germline mutations in one of the DNA mismatch repair (MMR) genes: MLH1 (chromosome 3p21.3),2, 3 MSH2 (chromosome 2p22–21),4 MSH6 (chromosome 2p16),5, 6 and PMS2 (chromosome 7p22.2)7, 8, or constitutional 3′ end deletions of EPCAM (chromosome 2p21).9, 10 These mutations cause 2–5% of all colorectal cancers11–16 and 10–15% of colorectal cancers diagnosed before age 50 years.11, 12, 17 They account for approximately 50% of the excess colorectal cancer cases observed in first-degree relatives of a colorectal cancer case.18 Reported estimates of carrier frequency of germline mutations of these genes in the population vary depending on differences in assumptions; from approximately 1 in 300 to 1 in 3000.15, 16, 19–22 Mutation carriers are at substantially increased risk of cancers of the colon, rectum, endometrium, stomach, ovary, uterine, renal pelvis, brain, small bowel and hepatobiliary tract, and the diagnoses of these cancers occur at younger ages than for the general population on average.23 Additionally, mutation carriers may also be at increased risk of cancer of the pancreas,24, 25 prostate,26 breast25, 27–29 and cervix.30

Screening colonoscopy,31, 32 prophylactic hysterectomy and bilateral salpingo-oophorectomy33 decrease the risk of colorectal, endometrial and ovarian cancer respectively for MMR gene mutation carriers. As a chemoprevention, 600 mg aspirin per day for an average two years has been shown to approximately halve the risk of colorectal cancer for MMR gene mutation carriers.34 Given the substantial risk of cancers and the availability of effective interventions to reduce risk, identifying mutation carriers can prevent or minimise the impact of a substantial number of cancers. Once carriers are identified, testing of their relatives can also be performed, and this will identify additional carriers who can also benefit from screening, and non-carriers who can be spared the intensive screening and prophylactic surgery recommended for their mutation-carrying relatives.

As germline testing is required to confirm mutation carrier status, untargeted testing is not cost-effective given the cost of germline sequencing and the rarity of carriers. Attempts have been made to develop criteria to categorise people by their probability of carrying a mutation, and prediction models have been developed to estimate a person’s probability of carrying a mutation. These criteria and models can be used to triage for germline sequencing. The aim of this review was to catalogue and describe the published criteria and prediction models, and to compare the performance of the prediction models for MMR gene mutation status.

CRITERIA AND GUIDELINES
Several criteria and guidelines have been developed for categorising families or individuals into those most likely to be carrying a MMR gene mutation so they can be triaged for germline testing. Given Lynch syndrome-associated colorectal cancers typically exhibit high level of DNA microsatellite instability (MSI) and/or loss of MMR protein expression that can be detected by immunohistochemistry (IHC), these techniques have been widely used as a screen for likely mutation carriers.
Here, we categorise these criteria as ‘clinical criteria’ if they are only based on personal and family history of cancer, including ages and sites of diagnoses, and as ‘clinicopathological criteria’ if they are based on tumour pathology as well as the clinical features described above.

**Clinical Criteria**

Amsterdam Criteria

Amsterdam Criteria-I developed by the International Collaborative Group on HNPCC (ICG-HNPCC) in 1990 is based only on family history of colorectal cancer (box 1). The strengths of the Amsterdam Criteria-I criteria are: (1) they do not take into account extracolonic cancers that are recognised as Lynch syndrome spectrum tumours; (2) they have reduced sensitivity for small families and (3) they require accurate recall and reporting of family history. Estimates of the Amsterdam Criteria-I sensitivity range between 47% and 91%, and specificity between 62% and 84% MMR gene mutations are observed in approximately 50% (positive predictive value) of families that met the Amsterdam Criteria-I.

In 1998, the ICG-HNPCC devised the Amsterdam Criteria-II which broadened the definition of family history by including specified extracolonic neoplasms.

---

**Box 1 Clinical criteria to identify mismatch repair gene mutations**

**Amsterdam Criteria-I (1990)**

- At least three relatives affected with CRC; one of them should be a first-degree relative to the other two
- At least two successive generations affected
- At least one affected relative with CRC before age 50 years
- Familial adenomatous polyposis should be excluded
- Tumours should be verified by pathological examination.

**Amsterdam Criteria-II (1998)**

- At least three relatives affected with an HNPCC-associated cancer (large bowel, endometrium, small bowel, ureter, or renal pelvis); one of them should be a first-degree relative of the other two
- At least two successive generations affected
- At least one relative affected with CRC before age 50 years
- Familial adenomatous polyposis should be excluded in the CRC case(s) if any
- Tumours should be verified by pathological examination.

**Modified Amsterdam Criteria (1993)**

- ‘Very small families’, which cannot be further expanded, can be considered as HNPCC even if there are only two CRCs in first-degree relatives; CRC must be present in at least two generations, and one or more CRC cases must be diagnosed under age 55 years
- In families with two first-degree relatives affected by CRC, the presence of a third relative with an early onset (before age 55 years) ‘unusual’ neoplasm or endometrial cancer is sufficient.
- Neoplasms are considered as ‘verified’ when histological reports, clinical charts, or death certificates are available.

**Mount Sinai Hospital Criteria (MC) (1995)**

- Three individuals in at least two successive generations with at least one CRC, and two others with either gastrointestinal, genitourinary or gynaecological cancers with no age limit for the cancer diagnosis (MC-1)
- Any CRC patient diagnosed at <35 years of age irrespective of family history of cancer (MC-2)
- Any individual with multiple primary cancers of the sites associated with HNPCC irrespective of family history of cancer (MC-3).

Familial adenomatous polyposis should be excluded.

**Japanese Criteria (1991)**

- CRC patient with two or more first-degree relatives with CRC
- CRC patient with one first-degree relative with CRC and any of the following:
  1. Age at onset of CRC(s) of less than 50 years.
  2. Right colon involvement.
  3. Synchronous and/or metachronous multiple CRCs.
  4. Associated extracolorectal malignancy.

Familial adenomatous polyposis should be excluded.

**Korean Criteria (1991)**

- Vertical transmission of CRC or at least two siblings in a family, affected with CRC
- Development of multiple colorectal tumours or at least one CRC case diagnosed before age 50 years.

**Chinese Criteria (2003)**

- At least two pathologically verified CRCs in a family; at least two of them first-degree relatives
- At least one of the following conditions has to be satisfied:
  1. At least one case with multiple colorectal cancers or adenomas
  2. At least one colorectal cancer diagnosed before age 50 years
  3. At least one case with an extracolonic cancer (gastric, endometrial, small bowel, ureter and renal pelvis, ovarian or hepatobiliary malignancies).

HNPCC, Hereditary Non-Polyposis Colorectal Cancer.
cancers. Consequently, sensitivity increased (range between 77% and 81%) though specificity decreased (between 46% and 68%).

Other clinical criteria

Other clinical criteria have been developed, including: modified Amsterdam Criteria, the Mount Sinai Hospital Criteria, Japanese Criteria, Korean Criteria and Chinese Criteria. (see detail in box 1). Note that all these clinical criteria are only used to identify Lynch syndrome families rather than individuals.

CLINICOPATHOLOGICAL CRITERIA

Bethesda guidelines

The Bethesda guidelines were developed in 1997 and revised in 2004 (box 2). MSI testing was recommended for any colorectal cancer case meeting at least one of the following criteria: Amsterdam-like family history of a range of cancers; particular pathological features of the tumour; and early age at diagnosis. Widening the inclusion criteria by adding indicators, resulted in increased sensitivity compared with the clinical criteria described above (89%, 95% CI 86% to 92%), and reduced specificity (53%, 95% CI 49% to 58%).

Box 2 Clinicopathological criteria to identify mismatch repair gene mutations

**Bethesda Guidelines (1997)**

Colorectal tumours should be tested for MSI in any of the following situations:

- Individuals with cancer in families that meet the Amsterdam Criteria
- Individuals with two HNPCC-related cancers, including synchronous and metachronous colorectal cancers or associated extracolonic cancers
- Individuals with colorectal cancer, and a first-degree relative with colorectal cancer and/or HNPCC-related extracolonic cancer and/or a colorectal adenoma; one of the cancers diagnosed at age <45 years, and the adenoma diagnosed at age <40 years
- Individuals with colorectal cancer or endometrial cancer diagnosed at age <45 years
- Individuals with right-sided CRC with an undifferentiated pattern (solid/cribriform) on histopathology diagnosed at age <45 years
- Individuals with CRC which was composed of >50% signet ring cells and diagnosed at age <45 years
- Individuals with adenomas diagnosed at age <40 years.


Colorectal tumours should be tested for MSI in any of the following situations:

- CRC diagnosed at age <50 years
- Presence of synchronous or metachronous HNPCC-related tumours, † regardless of age
- CRC with MSI-high histology diagnosed in individuals aged <60 years
- CRC diagnosed in one or more first-degree relatives with an HNPCC-related tumour, with one of the cancers being diagnosed at age <50 years
- CRC diagnosed in two or more first-degree or second-degree relatives with HNPCC-related tumours, † regardless of age

**Melbourne Criteria (2005)**

- Individuals with CRC diagnosed at age <45 years irrespective of family history should be tested for mismatch repair deficiency using IHC.

**Perth Criteria (2012)**

- Individuals with CRC diagnosed at age <60 years irrespective of family history should be tested for MSI.

**Jerusalem Recommendation (2010)**

- Individuals with CRC diagnosed at age <70 years irrespective of family history should be tested for MSI or mismatch repair deficiency using IHC.

*Endometrial, ovarian, gastric, hepatobiliary, small bowel, uterine and renal pelvis tumours.
†Colorectal, endometrial, stomach, small bowel, ovarian, pancreas, uterine and renal pelvis, biliary tract, and brain tumours, sebaceous gland adenomas and keratoacanthomas.
‡Presence of tumour-infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth pattern.

MLH1, Hereditary non-polyposis colorectal cancer; CRC, colorectal cancer; MSI, microsatellite instability; IHC, immunohistochemistry.
cost-effective compared with having an age of diagnosis cut-off before 50 years or before 70 years, while one study claimed that universal screening is more cost-effective than age-targeted testing.

None of these clinical and clinicopathological criteria provide the probability of being a MMR gene mutation carrier. They only indicate whether a colorectal cancer case should have their tumour tested for MSI and/or IHC testing, and depending on this result, to undergo germline testing for MMR gene mutations. These MSI and IHC tests require a pathologist, at least to select sections for staining. MSI testing needs to be conducted in a molecular laboratory, is more expensive, and does not provide information on which MMR gene is mutated, if any. Also, mutations cannot be identified for about one-third of those with a MMR-deficient colorectal cancer (even after screening for MLH1 methylation) tumour testing. The alternative of moving directly to germline testing, irrespective of tumour test results, would be too expensive and inefficient given only 2–5% of colorectal cancers are caused by germline MMR gene mutations. Further, studies have also shown that only a fraction of individuals who should be referred for molecular evaluation are actually referred.

### PREDICTION MODELS

#### Why are prediction models required for risk prediction of MMR gene mutations?

In addition to the limitations of all clinical and clinicopathological criteria that have been described above, they are not pertinent for: (1) individuals without colorectal cancer (except Amsterdam Criteria) and (2) individuals who have no relatives with colorectal cancer, who are able or willing to have their colorectal tumour tested for MMR-deficiency. For these individuals, statistical prediction models are needed to predict who are the most likely to be carriers based on their age and family history of colorectal and other Lynch syndrome spectrum cancers. Ideally, prediction models can quantitatively combine the complicated effects of many risk factors in a rational way; be easily updated when more accurate incidence data and population carrier frequencies become available; and are more widely applicable than clinical or clinicopathological criteria. For these reasons, risk prediction models for MMR gene mutations have been developed and used by physicians for their patients to help them decide whether to pursue germline testing or not.

### Existing risk prediction models for MMR gene mutations

The currently available risk prediction models for MMR gene mutations are as summarised in table 1: Leiden by Wijen et al, Amsterdam-plus by Lipton et al, Amsterdam-alternative by Lipton et al, MMRpro (previously known as CRCAPRO) by Chen et al, PREMM1,2 by Balmana et al and PREMM1,2,6 by Kastrinos et al, MMRpredict by Barnetson et al, AIFEG (Associazione Italiana per lo studio della Familiarità ed Ereditarietà dei tumori Gastrointestinali) by Marroni et al, and the Myriad Genetics Prevalence table.

All these models except MMRpredict and Myriad tables can predict the probability of carrying mutations for individuals or families with or without colorectal cancer. Leiden, Amsterdam-plus and Amsterdam-alternative models predict only at the family level while the other models predict at individual level. MMRpro and PREMM1,2,6 predict the probability of a mutation for each of the genes MLH1, MSH2 and MSH6, whereas the other models can only predict mutations in any MMR gene. None of the existing models take into account PMS2 mutations, which account for 15% of all MMR gene mutations and have different cancer risk profile than other MMR gene mutations. Apart from MMRpro, PREMM1,2 and PREMM1,2,6 the models only take into account history of colorectal cancer and endometrial cancer, but not other Lynch syndrome-associated cancers. All models used multivariable logistic regression methods for their model development except AIFEG, MMRpro and Myriad tables. AIFEG and MMRpro models require cancer data for full family pedigrees, and they applied Mendel’s genetic laws to predict mutations within family. On the other hand, Myriad tables just uses the prevalence of mutation among all tested colorectal cancer cases. Most of the models are easy to use as they all are web-based or based on a statistical formula (table 1).

### Evaluation of existing prediction models for MMR gene mutations

Before a risk prediction model can be recommended as a useful tool for individualised decision making in a clinical setting, it needs to be validated using an independent sample than that used to develop the model. The following characteristics were mainly evaluated by previous studies:

1. **Discrimination (or precision)**: The concordance statistic (c-statistic) that corresponds to the area under a receiver operating characteristic curve (AUC) which plots sensitivity against one minus specificity. A c-statistic of 0.5 indicates there is no discrimination between individuals who have mutations and those who do not, whereas 1.0 indicates perfect discrimination;

2. **Calibration (or reliability)**: The ratio of the expected number of events (E) with the observed number of events (O). The ratio 1.0 indicates perfect calibration;

3. **Accuracy**: Sensitivity, specificity, positive and negative predictive values of a model for a given probability threshold.

We reviewed all previously published studies that evaluated the performance of MMR gene prediction models. Most of the studies evaluated discrimination (using AUC) and a few studies also evaluated calibration and accuracy. We conducted meta-analyses of the AUCs for the PREMM, MMRpro, MMRpredict and Leiden models to summarise their discrimination performance; and these meta-analyses were stratified by population-based or clinic-based samples that were used for validation. As a sensitivity analysis, we conducted the meta-analyses on just the studies that reported results for the three models (PREMM, MMRpro, MMRpredict) within the same study. Both random and fixed effects were fitted, and heterogeneity was tested using I-squared. All statistical analyses were performed using Stata V11.0.

We observed a total of 17 studies that evaluated the performance of prediction models for MMR gene mutations (see online supplementary table S1). Of them, four used population-based samples,74 82–84 10 used clinic-based samples,71 72 75 85–91 and three used both clinic-based and population-based samples.73 92 93 Given there was significant evidence of heterogeneity between studies, we reported the pooled AUC values from random effect models (detail in table 2). The pooled AUC values from the combined analyses of population-based and clinic-based validation studies were 0.80 (95% CI 0.72 to 0.88) for MMRpro, 0.81 (95% CI 0.73 to 0.88) for MMRpredict, 0.84 (95% CI 0.81 to 0.88) for PREMM, and 0.85 (95% CI 0.78 to 0.91) for Leiden model (see online supplementary figures S1–4). When we restricted only to the seven studies (five clinic-based, one population-based and one both) validating three models within the same study, the AUCs were 0.81 (95% CI 0.72 to 0.89) for MMRpro, 0.78 (95% CI 0.68 to 0.89) for
4539 individuals (2526 affected with CRC) with a personal mutation carriers (58 MLH1, 870 CRC cases diagnosed age <55 years, recruited regardless, MSH2 16, 7 MSH6)

Literature review: meta-analyses of mutation frequencies

Win AK, et al (1998) and cancer

For the counselee penetrances and predictive value of MSI test and each FDR or SDR:

▸ Exa mutation

J Med Genet 250 families recruited from family cancer clinics; 34 (14%) mutation carriers (25 MLH1, 8 MSH2, 1 MSH6)

Table 1 Summary of existing risk prediction models for mismatch repair (MMR) gene mutations

<table>
<thead>
<tr>
<th>Year published</th>
<th>Leiden (^9)</th>
<th>Amsterdam-plus (^9)</th>
<th>Amsterdam-alternative (^9)</th>
<th>AIFEG (^5)</th>
<th>MMRpro (^7)</th>
<th>MMRpredict (^4)</th>
<th>PREMM (_1,2,6)</th>
<th>PREMM (_1,2,6)</th>
<th>Myriad (^7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRC affected/ unaffacted</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Affected only</td>
</tr>
<tr>
<td>Genes</td>
<td>MLH1, MSH2</td>
<td>MLH1, MSH2, MSH6</td>
<td>MLH1, MSH2, MSH6</td>
<td>MLH1, MSH2</td>
<td>MLH1, MSH2, MSH6</td>
<td>MLH1, MSH2</td>
<td>MLH1, MSH2</td>
<td>MLH1, MSH2, MSH6</td>
<td>MLH1, MSH2</td>
</tr>
<tr>
<td>Development dataset</td>
<td>184 CRC cases from 184 families; 47 (26%) mutation carriers (25 MLH1, 8 MSH2, 1 MSH6)</td>
<td>250 families recruited from family cancer clinics; 34 (14%) mutation carriers (25 MLH1, 8 MSH2, 1 MSH6)</td>
<td>Literature review: published estimates of mutation frequencies and cancer penetrances in carriers and non-carriers</td>
<td>Literature review: meta-analyses of mutation frequencies and cancer penetrances and predictive value of MSI test</td>
<td>870 CRC cases diagnosed age &lt;55 years, recruited regardless of family history; 38 (4%) mutation carriers (15 MLH1, 16 MSH2, 7 MSH6)</td>
<td>898 individuals (536 affected with CRC with a personal or family history of Lynch syndrome; 130 (15%) mutation carriers (58 MLH1, 72 MSH2)</td>
<td>4539 individuals (2526 affected with CRC with a personal or family history of Lynch syndrome; 525 (12%) mutation carriers (204 MLH1, 250 MSH2, 71 MSH6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development method</td>
<td>Multivariable logistic regression</td>
<td>Mutivariable logistic regression</td>
<td>Multivariable logistic regression</td>
<td>Application of the Mendelian laws</td>
<td>Application of the Mendelens laws</td>
<td>Multivariable logistic regression</td>
<td>Multivariable logistic regression</td>
<td>Not stated</td>
<td></td>
</tr>
<tr>
<td>Input</td>
<td>▸ Fulfillment of AC-II (yes/no)</td>
<td>▸ Mean age at diagnosis of CRC of affected relatives</td>
<td>▸ EC in family members (yes/no)</td>
<td>▸ Number of relatives with CRC</td>
<td>▸ Number of relatives with &gt;1 CRC and/or EC</td>
<td>▸ Number of relatives with EC</td>
<td>▸ Number of relatives with &gt;5 adenomas</td>
<td>▸ For the counselee and each relative: ▸ Exact relation to the counselee: ▸ Type of cancer ▸ Age at diagnosis of CRC if affected (&lt;45, 45–60, &gt;60 years) ▸ Current age or age at death or last follow-up (years) if unaffected ▸ Result of MSI testing (instability present or not present) if tumour available</td>
<td>▸ For the counselee: ▸ Age at diagnosis (years) ▸ Sex ▸ Tumour location (proximal, distal) ▸ Synchronous and/or metachronous (yes, no) ▸ For FDR: ▸ CRC (yes, no) ▸ Youngest age at diagnosis of CRC if affected (&lt;50 or ≥50 years) ▸ EC (yes, no)</td>
</tr>
<tr>
<td>CRC affected/ unaffacted</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Both affected and unaffected</td>
<td>Affected only</td>
</tr>
<tr>
<td>Genes</td>
<td>MLH1, MSH2</td>
<td>MLH1, MSH2, MSH6</td>
<td>MLH1, MSH2, MSH6</td>
<td>MLH1, MSH2</td>
<td>MLH1, MSH2, MSH6</td>
<td>MLH1, MSH2</td>
<td>MLH1, MSH2</td>
<td>MLH1, MSH2, MSH6</td>
<td>MLH1, MSH2</td>
</tr>
<tr>
<td>Development dataset</td>
<td>184 CRC cases from 184 families; 47 (26%) mutation carriers (25 MLH1, 8 MSH2, 1 MSH6)</td>
<td>250 families recruited from family cancer clinics; 34 (14%) mutation carriers (25 MLH1, 8 MSH2, 1 MSH6)</td>
<td>Literature review: published estimates of mutation frequencies and cancer penetrances in carriers and non-carriers</td>
<td>Literature review: meta-analyses of mutation frequencies and cancer penetrances and predictive value of MSI test</td>
<td>870 CRC cases diagnosed age &lt;55 years, recruited regardless of family history; 38 (4%) mutation carriers (15 MLH1, 16 MSH2, 7 MSH6)</td>
<td>898 individuals (536 affected with CRC with a personal or family history of Lynch syndrome; 130 (15%) mutation carriers (58 MLH1, 72 MSH2)</td>
<td>4539 individuals (2526 affected with CRC with a personal or family history of Lynch syndrome; 525 (12%) mutation carriers (204 MLH1, 250 MSH2, 71 MSH6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development method</td>
<td>Multivariable logistic regression</td>
<td>Mutivariable logistic regression</td>
<td>Multivariable logistic regression</td>
<td>Application of the Mendelian laws</td>
<td>Application of the Mendelens laws</td>
<td>Multivariable logistic regression</td>
<td>Multivariable logistic regression</td>
<td>Not stated</td>
<td></td>
</tr>
<tr>
<td>Input</td>
<td>▸ Fulfillment of AC-II (yes/no)</td>
<td>▸ Mean age at diagnosis of CRC of affected relatives</td>
<td>▸ EC in family members (yes/no)</td>
<td>▸ Number of relatives with CRC</td>
<td>▸ Number of relatives with &gt;1 CRC and/or EC</td>
<td>▸ Number of relatives with EC</td>
<td>▸ Number of relatives with &gt;5 adenomas</td>
<td>▸ For the counselee and each relative: ▸ Exact relation to the counselee: ▸ Type of cancer ▸ Age at diagnosis of CRC if affected (&lt;45, 45–60, &gt;60 years) ▸ Current age or age at death or last follow-up (years) if unaffected ▸ Result of MSI testing (instability present or not present) if tumour available</td>
<td>▸ For the counselee: ▸ Age at diagnosis (years) ▸ Sex ▸ Tumour location (proximal, distal) ▸ Synchronous and/or metachronous (yes, no) ▸ For FDR: ▸ CRC (yes, no) ▸ Youngest age at diagnosis of CRC if affected (&lt;50 or ≥50 years) ▸ EC (yes, no)</td>
</tr>
</tbody>
</table>

Continued
We have reviewed all major criteria and prediction models for MMR gene mutation status, which are currently available. This review is increasingly important, as consideration for who to screen and test for MMR gene mutations is now broader than it was in the past.

Overall, the existing prediction models are sensitive and specific with an AUC of approximately 90%. By contrast to the clinical or clinicopathological criteria that are dichotomous (yes/no for screening followed by germline testing), the prediction models provide a probability of having a MMR gene mutation for a family or an individual and, therefore, a cut-off point of probability needs to be set for when to test for the genetic mutation. Several levels have been suggested; for example, anyone with a 5% or greater probability of being carriers.

Dinh et al observed that direct germline testing for MMR gene mutations in people aged 25–35 years with a 5% or greater risk of being carriers predicted by PREMM1,2,6 could improve health outcomes in a cost-effective manner relative to current practice (initial screening by IHC and/or MSI followed by germline testing for colorectal cancer-affected people with a strong family history). This recommendation is in line with the National Comprehensive Cancer Network, which supports direct germline testing for MMR gene mutations for individuals with a 5% or greater risk of being carriers when a tumour sample is not readily available. For families in which there is no colorectal cancer tumour available for initial screening, this recommendation could result in numerous potential negative full gene screens and potentially increase costs compared within families where a colorectal tumour could be used for initial screening followed by germline testing.

Table 1

<table>
<thead>
<tr>
<th>Gene-specific estimates given</th>
<th>Leiden69</th>
<th>Amsterdam-plus70</th>
<th>Amsterdam-alternative70</th>
<th>AIFEG75</th>
<th>MMRpro71</th>
<th>MMRpredict74</th>
<th>PREMM1,272</th>
<th>PREMM1,2,673</th>
<th>Myriad76</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prediction level</td>
<td>Family</td>
<td>Family</td>
<td>Family</td>
<td>Family</td>
<td>Software</td>
<td>Software</td>
<td>Individual</td>
<td>Individual</td>
<td>Individual</td>
</tr>
<tr>
<td>Calculation mode</td>
<td>Formula (by hand)</td>
<td>Formula (by hand)</td>
<td>Formula (by hand)</td>
<td>Software (MLINK of the FASTLINK package)</td>
<td>Software (CancerGene)</td>
<td>Web-based</td>
<td>Web-based</td>
<td>Web-based</td>
<td>Prevalence table</td>
</tr>
<tr>
<td>Source of calculation mode</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>AIFEG website</td>
<td>MMRpro website, CancerGene software website</td>
<td>MMRpredict website</td>
<td>PREMM1,2 website</td>
<td>PREMM1,2,6 website</td>
<td>Myriad website</td>
</tr>
</tbody>
</table>

Table 2

<table>
<thead>
<tr>
<th>Model</th>
<th>Sample</th>
<th>Prevalence</th>
<th>p value</th>
<th>Heterogeneity</th>
<th>AUC, area under curve.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combined</td>
<td>88.4</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>41.5</td>
<td>0.11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>17.4</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>95.1</td>
<td>0.008</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>80.4</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>85.0</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>72.3</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>91.5</td>
<td>0.004</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>82.4</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>92.5</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>89.5</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>93.5</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>94.5</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>95.0</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3

<table>
<thead>
<tr>
<th>Model</th>
<th>Sample</th>
<th>Prevalence</th>
<th>p value</th>
<th>Heterogeneity</th>
<th>AUC, area under curve.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combined</td>
<td>88.4</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>41.5</td>
<td>0.11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>17.4</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>95.1</td>
<td>0.008</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>80.4</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>85.0</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>72.3</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>91.5</td>
<td>0.004</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>82.4</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>92.5</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>89.5</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>93.5</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>94.5</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based</td>
<td>95.0</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AUC, area under curve.
Kastrinos et al.92 97 98 proposed an algorithm for germline testing: IHC followed by MSI (and also BRAF testing for loss of MLH1 protein expression) in people diagnosed with colorectal cancer who have a 5% or greater probability of mutation according to PREMM.1,2,6. For a fast implementation of IHC analyses for MMR-deficiencies in combination with molecular analysis of BRAF mutations and/or MLH1 promoter methylation, new technology will be required as part of the diagnostic setting for all Lynch syndrome-associated cancers. Further, implementation of targeted sequencing of genes by next-generation sequencing will probably challenge the diagnostics of Lynch syndrome as it is expected to deliver lower costs and faster time of analysis.

Currently, all these models are free and publicly available. The cut-off level needs to be set by individual clinics depending on their resources and the proportion of mutation carriers they want to identify. Future models may need to: (1) provide prediction of PMS2 mutations, (2) take into account a wider range of Lynch syndrome-associated cancers when assessing family history and (3) be applicable to all people irrespective of any cancer diagnosis.

Contributors AKW carried out study concept and design, literature review, collection and assembly of data, analysis and interpretation of data, drafting and final approval of manuscript. RJM, JGD and MAI carried out study concept and design, interpretation of data, drafting and final approval of manuscript.

Funding AKW is supported by the Picchi Brothers Foundation Cancer Foundation Victoria Cancer Research Scholarship, Australia. MAI is a National Health and Medical Research Council Senior Research Fellow, Australia.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

17. Hopper JL. Application of genetics to the prevention of colorectal cancer. Recent Results Cancer Res 2005;166:17–33.
Review


32 de Jong AE, Hendriks BM, Mackie J, Beijersbergen RL, Cats A, Grif

33 fi

34 de Jong AE, Hendriks YMC, Kleibeuker JH, de Boer SY, Cats A, Grif

35 fi


76 Myriad Genetic Laboratories, MLH1 and MSH2 Prevalence Table. 2007.


81 StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP, 2009.


